M Pharmaceutical Inc.

M Pharmaceutical Inc.

May 14, 2015 09:00 ET

Dr. Christopher Andrews M.D., MSc, FRCPC Joins the Board of M Pharmaceutical Inc.

VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 14, 2015) - Dr. Christopher Andrews, M.D., MSc, FRCPC, a highly-respected Gastroenterologist, faculty member of the Department of Medicine at the University of Calgary and graduate of the Mayo Clinic in Rochester, MN, is joining the Board of Directors of M Pharmaceutical Inc. (the "Company") (CSE:MQ).

Dr. Andrews, who specializes in stomach disorders and physiology, is the latest leadership asset to join the Company, which is committed to developing and commercializing innovative biomedical technologies that improve the health and quality of life for people affected by obesity or diabetes.

"We're delighted to have someone of Dr. Andrews' background and profile join our organization and help us advance our vision for biomedical technologies designed to improve the lives of those dealing with obesity and diabetes," said Dr. Martin Mintchev, the President & Chief Executive Officer of the Company. "His addition to our Board of Directors will help ensure that we make the most of our vision and strategic plan reflected in technologies such as the e-Mosquito wearable blood glucose monitor, the implantable gastro-intestinal neuro stimulators and the ingestible pseudobezoars."

Dr. Andrews is a Clinical Associate Professor at the University of Calgary. He has had advanced training in gastrointestinal motility and function at the Mayo Clinic, where he also obtained a Masters Degree in Clinical Health Research. Dr. Andrews also specializes in the development of novel diagnostic and therapeutic methods related to gut function. He went to McMaster Medical School, followed by residencies in Internal Medicine and Gastroenterology at the University of British Columbia and University of Calgary, respectively.

Dr. Andrews has won many awards, including a Young Investigator Award from the American Motility Society for his research on the effects of glucagon-like peptide-1 on gastric accommodation, and is currently the Canadian Association of Gastroenterology Visiting Clinical Professor. He has published over 50 peer-reviewed articles and has numerous teaching citations from the University of Calgary Medical School.

Dr. Mintchev also acknowledged the contributions of David Lane of Coquitlam, B.C. to the growth and development of the Company: "We're in a strong position to continue our growth and fulfil our vision thanks largely to the work of David Lane as our inaugural President of the Company. As he leaves the board, we wish him all the best in his new endeavours and thank him for his service."

About M Pharmaceutical Inc.

M Pharmaceutical Inc. is committed to developing and commercializing innovative biomedical technologies that improve the health and quality of life of people affected by obesity and diabetes. The Company currently has or has agreed to acquire the exclusive rights to a family of biomedical technologies including (i) the eMosquito, for automatic and autonomous monitoring of blood glucose by diabetics; (ii) temporary controllable pseudobezoars, an innovative method for non-invasive dynamic gastric volume reduction for weight loss; and (iii) gastrointestinal neuro-stimulators using a laparoscopically-implantable technique for the treatment of obesity without permanent anatomical modification of the stomach.


This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the commercialization of the rights to the eMosquito and the temporary pseudobezoars. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com and such factors as the Company failing to complete the commercialization of the eMosquito and the temporary pseudobezoars.

Contact Information